Literature DB >> 22484348

BALB/c mice, but not C57BL/6 mice immunized with a ΔclpB mutant of Francisella tularensis subspecies tularensis are protected against respiratory challenge with wild-type bacteria: association of protection with post-vaccination and post-challenge immune responses.

Susan Twine1, Hua Shen, Gregory Harris, Wangxue Chen, Anders Sjostedt, Patrik Ryden, Wayne Conlan.   

Abstract

Francisella tularensis subspecies tularensis is highly virulent for humans especially when it is inhaled. Therefore, it has the potential to be used as a biothreat agent. Vaccines against F. tularensis will need to be approved in accordance with the FDA Animal Rule. This will require identification of robust correlates of protection in experimental animals and the demonstration that similar immune responses are generated in vaccinated humans. Towards this goal, we have developed an experimental live vaccine strain by deleting the gene, clpB, encoding a heat shock protein from virulent subsp. tularensis strain, SCHU S4. SCHU S4ΔclpB administered intradermally protects BALB/c, but not C57BL/6 mice from subsequent respiratory challenge with wildtype SCHU S4. A comparison of post-vaccination and post-challenge immune responses in these two mouse strains shows an association between several antibody and cytokine responses and protection. In particular, elevated IFNγ levels in the skin 2 days after vaccination, sero-conversion to hypothetical membrane protein FTT_1778c, and to 30S ribosomal protein S1 (FTT_0183c) of F. tularensis after 30 days of vaccination, and elevated levels of pulmonary IL-17 on day 7 after respiratory challenge with SCHU S4 were all associated with protection.
Copyright © 2012 Wayne Conlan. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22484348     DOI: 10.1016/j.vaccine.2012.03.036

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  31 in total

1.  Enhancement of antigen-specific immunoglobulin G responses by anti-CD48.

Authors:  Dorothy Yuan; Yuhong Guo; Suwannee Thet
Journal:  J Innate Immun       Date:  2012-11-27       Impact factor: 7.349

2.  Identification of mechanisms for attenuation of the FSC043 mutant of Francisella tularensis SCHU S4.

Authors:  Marie Lindgren; Linda Tancred; Igor Golovliov; Wayne Conlan; Susan M Twine; Anders Sjöstedt
Journal:  Infect Immun       Date:  2014-06-16       Impact factor: 3.441

3.  Novel catanionic surfactant vesicle vaccines protect against Francisella tularensis LVS and confer significant partial protection against F. tularensis Schu S4 strain.

Authors:  Katharina Richard; Barbara J Mann; Lenea Stocker; Eileen M Barry; Aiping Qin; Leah E Cole; Matthew T Hurley; Robert K Ernst; Suzanne M Michalek; Daniel C Stein; Philip Deshong; Stefanie N Vogel
Journal:  Clin Vaccine Immunol       Date:  2013-12-18

4.  Proteomic analysis and immunogenicity of Mannheimia haemolytica vesicles.

Authors:  Sahlu Ayalew; Anthony W Confer; Binu Shrestha; Amanda E Wilson; Marie Montelongo
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

5.  Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells.

Authors:  Amanda J Griffin; Deborah D Crane; Tara D Wehrly; Catharine M Bosio
Journal:  Clin Vaccine Immunol       Date:  2014-11-19

6.  Next Generation Vaccine Biomarkers workshop October 30-31, 2014--Ottawa, Canada.

Authors:  Susan M Twine; Kelly M Fulton; John Spika; Marc Ouellette; Jennifer F Raven; J Wayne Conlan; Lakshmi Krishnan; Luis Barreto; James C Richards
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 7.  Tularemia vaccines.

Authors:  Daniela Putzova; Iva Senitkova; Jiri Stulik
Journal:  Folia Microbiol (Praha)       Date:  2016-05-19       Impact factor: 2.099

8.  Infection with Francisella tularensis LVS clpB leads to an altered yet protective immune response.

Authors:  Lydia M Barrigan; Shraddha Tuladhar; Jason C Brunton; Matthew D Woolard; Ching-ju Chen; Divey Saini; Richard Frothingham; Gregory D Sempowski; Thomas H Kawula; Jeffrey A Frelinger
Journal:  Infect Immun       Date:  2013-03-25       Impact factor: 3.441

Review 9.  Live attenuated tularemia vaccines: recent developments and future goals.

Authors:  Mark E Marohn; Eileen M Barry
Journal:  Vaccine       Date:  2013-06-10       Impact factor: 3.641

10.  Identification of a live attenuated vaccine candidate for tularemia prophylaxis.

Authors:  Manish Mahawar; Seham M Rabadi; Sukalyani Banik; Sally V Catlett; Dennis W Metzger; Meenakshi Malik; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2013-04-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.